Table 2.
Pulmonary microbiology, 2014 ivacaftor and comparator cohorts, US CFFPR and UK CFR
| Microorganism | US CFFPR | UK CFR | ||||
| Prevalence in patients with bacterial cultures, n (%) | χ2 P values | Prevalence in patients with bacterial cultures, n (%) | χ2 P values | |||
| Ivacaftor (n=1226) |
Comparator (n=5960) |
Ivacaftor (n=409) |
Comparator (n=2033) |
|||
| Staphylococcus aureus | 784 (63.9) | 4166 (69.9) | <0.0001 | 122 (29.8) | 689 (33.9) | 0.1706 |
| MRSA | 286 (23.3) | 1751 (29.4) | <0.0001 | 11 (2.7) | 75 (3.7) | 0.4166 |
| Pseudomonas aeruginosa | 565 (46.1) | 3354 (56.3) | <0.0001 | 188 (46.0) | 1113 (54.7) | 0.0014 |
| Haemophilus influenzae | 162 (13.2) | 675 (11.3) | 0.0605 | 53 (13.0) | 220 (10.8) | 0.2105 |
| Stenotrophomonas (Xanthomonas) maltophilia | 133 (10.8) | 893 (15.0) | 0.0002 | 21 (5.1) | 166 (8.2) | 0.0522 |
| Mycobacterium* | 66 (9.9) | 430 (11.8) | 0.1479 | 1 (0.2) | 10 (0.5) | 1.0000 |
| Aspergillus spp | 131 (10.7) | 1123 (18.8) | <0.0001 | 42 (10.3) | 410 (20.2) | <0.001 |
| Alcaligenes (Achromobacter) xylosoxidans | 68 (5.5) | 471 (7.9) | 0.0043 | 18 (4.4) | 67 (3.3) | 0.3110 |
| Burkholderia cepacia complex | 38 (3.1) | 197 (3.3) | 0.7121 | 17 (4.2) | 104 (5.1) | 0.5222 |
| Klebsiella spp | 17 (1.4) | 90 (1.5) | 0.7452 | 4 (1.0) | 7 (0.3) | 0.0935 |
| Pandoraea spp | 2 (0.2) | 12 (0.2) | 1.0000 | 0 (0) | 0 (0) | – |
*In the US CFFPR, prevalence of Mycobacterium is based on patients with available cultures (ivacaftor cohort, n=670; comparator cohort, n=3647).
CFFPR, Cystic Fibrosis Foundation Patient Registry; CFR, Cystic Fibrosis Registry; MRSA, methicillin-resistant S. aureus; spp, species (any or all, not specified).